Newark, DE, United States of America

James Jeffrey Folmer

USPTO Granted Patents = 9 

 

Average Co-Inventor Count = 5.3

ph-index = 3

Forward Citations = 47(Granted Patents)


Location History:

  • Newark, DE (US) (2002)
  • Wilmington, DE (US) (2007 - 2013)

Company Filing History:


Years Active: 2002-2013

Loading Chart...
Loading Chart...
9 patents (USPTO):

Title: James Jeffrey Folmer: Innovator in Pharmaceutical Chemistry

Introduction

James Jeffrey Folmer is a notable inventor based in Newark, DE (US). He has made significant contributions to the field of pharmaceutical chemistry, holding a total of 9 patents. His work primarily focuses on the development of innovative compounds that have potential therapeutic applications.

Latest Patents

Among his latest patents is a groundbreaking invention related to oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators. This patent, numbered 842, details compounds of Formula (I) wherein R and Q are as described in the specification. It also covers pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing these compounds, and methods for using the same.

Career Highlights

James Jeffrey Folmer has established a successful career at AstraZeneca AB, where he continues to contribute to advancements in drug development. His expertise in pharmaceutical chemistry has positioned him as a key player in the industry, driving innovation and research.

Collaborations

Throughout his career, Folmer has collaborated with esteemed colleagues, including James Empfield and Joseph Cacciola. These partnerships have fostered a collaborative environment that enhances the research and development process.

Conclusion

James Jeffrey Folmer's contributions to pharmaceutical chemistry and his innovative patents underscore his importance in the field. His work continues to pave the way for new therapeutic solutions, demonstrating the impact of dedicated inventors in advancing healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…